HJ Science Company Description

HJ Science Co., Ltd. engages in research and development of new small molecule drugs in the People’s Republic of China.

It focuses on autoimmune, metabolic diseases, and oncology disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the topical treatment of atopic dermatitis (AD), acne vulgaris (AV), neurodermatitis (ND), and psoriasis (PS), as well as oral treatment of AD, AV, ND, and PS in the autoimmune sector; HJ178, an orally available agent for type 2 diabetes, and potentially overweight or obesity in the metabolic sector; and HJ891, an oral KRAS inhibitor intended for the treatment of non-small-cell lung cancer.

It is also developing HJ197 in clinical-stage for treatment of hepatocellular carcinoma and solid tumors; and five preclinical drug candidates comprising HJ356, HJ093, HJ199, HJ198, and HJ086 for treatment of cardiovascular disease and atherosclerosis.

The company was incorporated in 2017 and is headquartered in Chengdu, China.

HJ Science Co., Ltd.

Country	China
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	113
CEO	Jianxin Ji

Contact Details

Address: No. 501,Building 4 Chengdu China
Website	hj3h.com

Stock Details

Ticker Symbol	6132
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100007PD2
SIC Code	2834

Key Executives

Name	Position
Dr. Jianxin Ji	Chief Executive Officer, GM and Executive Chairman of the Board
Xiangyu Yang	Chief Operating Officer and Executive Director
Yao Zhang	Deputy Head of Human Resource and Executive Director
Zhen Wu	Deputy Chief Operating Officer and Executive Director
Jingjie Zhang	Chief Financial Officer and Joint Board secretary
Liqun Wang	Head of Administration Department and Supervisor
Shuai Luo	Head of Project Department
Dr. Guo Na	Head of Research and Development
Wing Yee Ma	Joint Company Secretary